Physician profile
Reena Dave
NPI 1689099004
$483.66
in general payments reported to CMS, 2019-2025
11 companies · $31.14 in 2025
The $31.14 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $143 · 2024: $309 · 2025: $31.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $122.01 | 2024 | Carto 3 |
| Lilly USA, LLC | $102.15 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $48.38 | 2023-2024 | Ozempic, Rybelsus |
| Mannkind Corporation | $42.49 | 2023-2024 | Afrezza |
| Medtronic, INC. | $32.67 | 2024 | Minimed 780g |
| Cequr Corporation | $32.41 | 2024 | Cequr Simplicity |
| Insulet Corporation | $23.90 | 2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $21.89 | 2023 | Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.56 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $20.87 | 2024 | |
| Halozyme INC | $15.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.